Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Carlier

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Seminars in Oncology|December 3, 2014
Radioimmunoconjugates for the treatment of cancerFrançoise Kraeber-Bodéré, Caroline Bodet-Milin, Caroline Rousseau, et al.
EJNMMI Research|July 1, 2026
Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric studySolène Perret, Léa Albe, Agathe Edet-Sanson, et al.
Clinical Nuclear Medicine|December 14, 2020
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine TumorsCatherine Ansquer, Yann Touchefeu, Alain Faivre-Chauvet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2018
Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM StudyClément Bailly, Thomas Carlier, Bastien Jamet, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2018
<sup>18</sup>F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL PatientsSylvain Chantepie, Narinée Hovhannisyan, Stéphane Guillouet, et al.
International Journal of Molecular Sciences|May 30, 2019
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between <sup>89</sup>Zr- and <sup>64</sup>Cu-Labeled Anti-CD138 in a Preclinical Syngeneic ModelClément Bailly, Sébastien Gouard, François Guérard, et al.
Haematologica|August 3, 2019
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET ProjectClément Bailly, Thomas Carlier, Alina Berriolo-Riedinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2021
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC StudyCaroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 28, 2022
Molecular Signature of <sup>18</sup>F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET StudyJean-Baptiste Alberge, Françoise Kraeber-Bodéré, Bastien Jamet, et al.
Blood|September 24, 2025
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trialFrançoise Kraeber-Bodéré, Bastien Jamet, Sonja Zweegman, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Seminars in Oncology|December 3, 2014
Radioimmunoconjugates for the treatment of cancerFrançoise Kraeber-Bodéré, Caroline Bodet-Milin, Caroline Rousseau, et al.
EJNMMI Research|July 1, 2026
Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric studySolène Perret, Léa Albe, Agathe Edet-Sanson, et al.
Clinical Nuclear Medicine|December 14, 2020
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine TumorsCatherine Ansquer, Yann Touchefeu, Alain Faivre-Chauvet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2018
Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM StudyClément Bailly, Thomas Carlier, Bastien Jamet, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 9, 2018
<sup>18</sup>F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL PatientsSylvain Chantepie, Narinée Hovhannisyan, Stéphane Guillouet, et al.
International Journal of Molecular Sciences|May 30, 2019
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between <sup>89</sup>Zr- and <sup>64</sup>Cu-Labeled Anti-CD138 in a Preclinical Syngeneic ModelClément Bailly, Sébastien Gouard, François Guérard, et al.
Haematologica|August 3, 2019
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET ProjectClément Bailly, Thomas Carlier, Alina Berriolo-Riedinger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2021
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC StudyCaroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 28, 2022
Molecular Signature of <sup>18</sup>F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET StudyJean-Baptiste Alberge, Françoise Kraeber-Bodéré, Bastien Jamet, et al.
Blood|September 24, 2025
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trialFrançoise Kraeber-Bodéré, Bastien Jamet, Sonja Zweegman, et al.
Pageof 9